Jen-Yu Hsu

Dr. Jen-Yu Hsu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
JHJen-Yu Hsu
Jen-Yu Hsu
YCYu-Chung Chuang
Yu-Chung Chuang
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
Yang-ching ChenYang-ching Chen
Yang-ching Chen
SHSZU-MIN HSIEH
SZU-MIN HSIEH
In Taiwan, carbapenem-resistant Klebsiella pneumoniae (CRKP) now became a leading cause of difficult-to-treat healthcare-associated infection, for which there are a lack of recent hospital epidemiological studies on risk factors, mortality, and antimicrobial susceptibility. We prospectively enrolled patients with healthcare-associated CRKP monomicrobial bloodstream infection (mBSI) and matched patients with carbapenem susceptible K. pneumoniae (CSKP) mBSI at National Taiwan University Hospital (Taipei, Taiwan) from October 2017 through December 2019 in a 1:2 ratio. Multivariable logistic regression and Kaplan-Meier analyses were applied to identify factors associated with CRKP mBSI and to compare the 14-day survival curves, respectively. We detected the presence of blaKPC and blaNDM gene among the included CRKP strains, and performed antimicrobial susceptibility testing (including susceptibility to colistin, aminoglycoside, tigecycline, and ceftazidime/avibactam). A total of 36 CRKP cases and 72 CSKP controls were enrolled. Patients with CRKP mBSI were more likely to have liver cirrhosis (adjusted odds ratio [aOR], 5.61; P = 0.024), length of hospital stay over the previous 14 days (aOR, 1.23; P = 0.001) and prior use of carbapenems in the previous 14 days (aOR, 6.07; P = 0.004) than patients with CSKP mBSI. The 14-day survival was significantly worse for patients with CRKP mBSI than those with CSKP mBSI (all CRKP cases: 50.0% vs. 87.5%; P < 0.001; CRKP cases treated with colistin as an appropriate backbone antibiotic: 58.3% vs. 87.5%; P = 0.007). Compared with the CSKP isolates, CRKP isolates were significantly less susceptible to colistin, amikacin, and tigecycline. Of the 36 CRKP isolates, none harbor blaNDM gene and 35 (97%) had low minimum inhibitory concentrations (≤8/4 μg/ml) of ceftazidime/avibactam by the E test method. Prior exposure to carbapenems, longer hospital stay, and the presence of liver cirrhosis predicted CRKP instead of CSKP mBSI. Even with colistin therapy, CRKP mBSIs was still associated with a very high risk of mortality within 14 days. Ceftazidime/avibactam is a potentially useful therapeutic choice for cases caused by in vitro susceptible CRKP strains.

23 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JHJen-Yu Hsu
Jen-Yu Hsu
Yan-Chiao MaoYan-Chiao Mao
Yan-Chiao Mao
PLPo-Yu Liu
Po-Yu Liu
KLKuo-Lung Lai
Kuo-Lung Lai
Some effective drugs have been approved or issued an Emergency Use Authorization for the treatment of COVID-19 in hospitalized patients, but post-market surveillance is warranted to monitor adverse events. We reviewed clinical trials and case reports in patients with moderate-to-severe COVID-19 infection who received remdesivir, baricitinib, tocilizumab, or sarilumab. The drug-specific pharmacokinetics, toxicity, and drug interactions are summarized in this study. Remdesivir and baricitinib are small-molecule drugs that are mainly metabolized by the kidneys, while tocilizumab and sarilumab are monoclonal antibody drugs with metabolic pathways that are currently not fully understood. The most common adverse events of these drugs are alterations in liver function, but serious adverse events have rarely been attributed to them. Only a few studies have reported that remdesivir might be cardiotoxic and that baricitinib might cause thromboembolism. Biological agents such as baricitinib, tocilizumab, and sarilumab could inhibit the pathway of inflammatory processes, leading to immune dysregulation, so the risk of secondary infection should be assessed before prescribing. Further recognition of the pathogenic mechanism and risk factors of adverse events is essential for optimizing treatment strategies.

2 October 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JHJen-Yu Hsu
Jen-Yu Hsu
CHChien-Ching Hung
Chien-Ching Hung
TTTsung-Pei Tsou
Tsung-Pei Tsou
WCWan-Chin Chen
Wan-Chin Chen
Introduction: Taiwan introduced a two-dose inactivated Japanese encephalitis (JE) mouse brain-derived (JE-MB) vaccine into routine childhood immunization in 1968, with booster vaccination implemented in 1974 and 1983. In 2017, JE-MB vaccine was replaced by a two-dose live-attenuated chimeric vaccine (JE-CV). After implementation of JE vaccination programs, JE cases have shifted from children to adults. In this study, we described the JE epidemiology and identify high-risk groups to further inform vaccine policy. Methodology/Principal findings: We extracted data from Taiwan’s notifiable disease surveillance database, vital statistics, and employment statistics from 2010 to 2022. Diagnosis of JE was confirmed by JE seroconversion, a four-fold increase in virus-specific antibodies, a positive JE viral nucleic-acid test, or JE virus isolation. From 2010 to 2022, a total of 313 cases of JE were diagnosed, resulting in an overall incidence rate of 0.10 cases per 100,000 person-years and a mortality rate of 0.006 per 100,000 population per year. Among these patients, 64% were male, and the median age was 51 years (range 0–82). Compared with people born in or after 1976 (vaccinated with four doses of JE-MB vaccine or two doses of JE-CV), those born in or before 1962 (unvaccinated) and those born during 1963–1975 (vaccinated with two or three doses of JE-MB vaccine) had a 4.2-fold (95% confidence interval [CI] 3.0–5.7) and 5.9-fold (95% CI 4.3–8.1) higher risk of JE, respectively. The relative risk of working in agriculture, forestry, fishing, or animal husbandry, compared to other occupations, was 5.0 (95% CI 3.5–7.0). Conclusions/Significance: In Taiwan, individuals born before 1976 and those employed in agriculture, forestry, fishing, or animal husbandry had a higher risk of JE. We recommend JE vaccination for people in these high-risk groups who have not been fully vaccinated or have an unknown vaccination history.

1 January 2025 in Helicobacter
Verified
Journal Article
Closed access
JHJen-Yu Hsu
Jen-Yu Hsu
UWUn‐In Wu
Un‐In Wu
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
WSWang-Huei Sheng
Wang-Huei Sheng
Yang-ching ChenYang-ching Chen
Yang-ching Chen
SCShan‐Chwen Chang
Shan‐Chwen Chang

13 February 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
JHJen-Yu Hsu
Jen-Yu Hsu
HSHSIN-YUN SUN
HSIN-YUN SUN
THTan-Wen Hsieh
Tan-Wen Hsieh
SCSui-Yuan Chang
Sui-Yuan Chang
YCYu-Chung Chuang
Yu-Chung Chuang
CHChien-Ching Hung
Chien-Ching Hung
We aimed to investigate the incidence of low-level viremia (LLV) and its impact on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy (ART) who switched to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/c/FTC/TAF). PLWH aged 18 years or older who had received ART with plasma HIV RNA load (PVL) <50 copies/mL for 6 months or longer and switched to EVG/c/FTC/TAF between March and October 2018 were retrospectively included. The incidence of LLV (defined as PVL of 50-999 copies/mL) and VF (PVL ≥1000 copies/mL) was calculated and represented by Kaplan-Meier plots. The generalised estimating equation model was constructed to identify factors associated with LLV and VF. Resistance-associated mutations were determined using population sequencing. A total of 1078 PLWH were included. The incidence rates of LLV and VF after the switch to EVG/c/FTC/TAF were 3.5 and 0.8 events per 100 person-years of follow-up, respectively, whereas the respective cumulative incidence of LLV and VF reached 11.7% and 2.9% within 3 years of follow-up. LLV was associated with any LLV episode before or after the switch and prior exposure to integrase strand transfer inhibitor-based ART. VF was associated with any LLV before or after the switch and prior exposure to raltegravir, but not the level or frequency of LLV. The risks of LLV and VF were low in PLWH who had achieved virologic suppression and switched to EVG/c/FTC/TAF, and the presence of LLV and prior exposure to raltegravir increased the risk of VF.

1 November 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
JHJen-Yu Hsu
Jen-Yu Hsu
HSHSIN-YUN SUN
HSIN-YUN SUN
LCLing-Ya Chen
Ling-Ya Chen
SCSui-Yuan Chang
Sui-Yuan Chang
YCYu-Chung Chuang
Yu-Chung Chuang
CHChien-Ching Hung
Chien-Ching Hung
We aimed to investigate the evolution of weight, lipid profiles, and glucose homeostasis among virally-suppressed people living with HIV (PLWH) who switched to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). PLWH with viral suppression who switched to BIC/FTC/TAF between October 2019 and May 2021 were followed for 96 weeks to examine the change of weight, lipid profiles (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG)), and glycated hemoglobin (HbA1c) levels. 889 PLWH with an average weight of 72.1 kg at baseline were included. At week 96, over 95% of PLWH consistently maintained plasma HIV RNA load <50 copies/mL at each 24-week interval of follow-up while the weight change was small (+0.7 kg, p<0.0001), though statistically significant. Baseline levels of TC, LDL-C, HDL-C, TG, and HbA1c were 191.8 mg/dL, 114.2 mg/dL, 48.9 mg/dL, 174.3 mg/dL, and 5.31%, respectively. After 96 weeks, changes were observed in TC (-11.6 mg/dL, p<0.0001), LDL-C (-3.4 mg/dL, p=0.0084), HDL-C (+0.6 mg/dL, p=0.1089), TG (-30.2, p<0.0001), and HbA1c (+0.12%, p<0.0001). A 5% or more weight gain was associated with age of 30-40 years, normal weight at baseline, and prior use of non-integrase inhibitors or tenofovir disoproxil fumarate. Obesity was associated with development of both dyslipidemia and diabetes mellitus after switch. Stable switch to BIC/FTC/TAF maintained high rates of viral suppression and had a small impact on weight and metabolic changes in virally suppressed PLWH. Follow-up of the weight and metabolic changes is warranted in PLWH on long-term antiretroviral therapy.